site stats

Syros pharmaceuticals merger

WebSep 15, 2024 · The new CUSIP number for Syros’ common stock following the reverse stock split is 87184Q206. On September 15, 2024, the holders of a majority of Syros’ … WebNov 14, 2024 · Closed Merger with TYME Technologies and Concurrent PIPE; Proceeds from Combined Transactions Augment Cash Balance, Ending Third Quarter with …

Press Releases :: Syros Pharmaceuticals, Inc. (SYRS)

WebAug 9, 2024 · Definitive Merger Agreement with TYME Technologies and Concurrent PIPE Expected to Close 2H 2024 and Bring Combined Proceeds of Approximately $190 Million, … WebSep 15, 2024 · Following the closing of the Merger, the combined company will trade on The Nasdaq Global Select Market under the ticker symbol "SYRS," and will be led by Syros’ existing management team,... germ killing shower light https://ladonyaejohnson.com

Syros Pharmaceuticals To Acquire TYME Technologies

WebApr 15, 2024 · Syros Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $12.93. Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) last released its quarterly earnings … WebKEY WINS: Steered the strategic and operational integration of Tyme Inc. into Syros Pharmaceuticals following an acquisition. Now driving business for an artificial intelligence-powered... WebApr 7, 2024 · Syros Pharmaceuticals is part of the Pharmaceuticals industry, and located in Massachusetts, United States. Syros Pharmaceuticals Location 35 Cambridge Park Dr, Cambridge, Massachusetts, 02140, United States Description Read More Industry Pharmaceuticals Healthcare Discover more about Syros Pharmaceuticals Beth Ann Work … germ layer in porifera

Syros Pharmaceuticals, Inc. (SYRS)

Category:Syros Pharmaceuticals, Inc. (SYRS)

Tags:Syros pharmaceuticals merger

Syros pharmaceuticals merger

TYME Technologies Shares Surge On Merger Agreement With …

WebSep 16, 2024 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of … WebJul 5, 2024 · Development stage biotech firms Syros Pharmaceuticals ( SYRS) and Tyme Technologies ( NASDAQ: TYME) announced on Tuesday that the companies entered into …

Syros pharmaceuticals merger

Did you know?

WebMar 2, 2024 · Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Dec 12, 2024 Syros Pharmaceuticals Announces Publication in Blood Advances … WebJul 5, 2024 · In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME’s expected net cash at closing and …

WebAt Syros, we have identified cancer patients with aberrant expression of genes that can be targeted with new therapies. We are focused on applying this approach to developing … WebSep 15, 2024 · Following the closing of the Merger, the combined company will trade on The Nasdaq Global Select Market under the ticker symbol “SYRS,” and will be led by Syros’ …

WebTyme Technologies, Inc., a biotechnology company developing cancer metabolism-based therapies, completed its acquisition by merger with Syros Pharmaceuticals, Inc., a leader …

WebJul 5, 2024 · Concurrent with the merger, Syros announced an oversubscribed $130 million private investment in public equity (PIPE) financing at a price per unit of $0.94. New and …

WebSyros Pharmaceuticals, Inc. 35 CambridgePark Drive, 4th Floor . Cambridge, Massachusetts 02140 (617) 744-1340 (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) Copies to: Nancy Simonian, M.D. President and Chief Executive Officer. germ layer derivative of the facial bonesWebJul 5, 2024 · Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement News Download as PDF July 05, 2024 Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance … germ layers gives rise to the gastrocnemiusWebNov 22, 2024 · Syros and Tyme Technologies Announce Stockholder Approval of Merger Sep 13, 2024 Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment … germ layer formationWebSyros Pharmaceuticals, Inc., a Delaware corporation, or Syros, and Tyme Technologies, Inc., a Delaware corporation, or Tyme, entered into an Agreement and Plan of Merger, or the … germ layers biologyWebJul 5, 2024 · In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME's expected net cash at closing and … christmas dot marker coloring pageWebSep 20, 2024 · Syros Pharmaceuticals has recently acquired its peer Tyme Technologies. The sole purpose of the merger was to acquire TYME's cash balance. Concurrently with … germ killing light used in hospitalWebJul 5, 2024 · Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement Business Wire July 5, 2024, 4:00 AM · 16 … germ layers of fasciola hepatica